Drug pricing
Featured Topics
Lead story
Other featured articles
-
Drug Rebates in Medicare Part D
On July 27, the USC-Brookings Schaeffer Initiative for Health Policy will host a webinar to discuss how the increasing reliance on rebates burdens many Medicare patients and policy solutions.
Posted in -
Reducing Racial Disparities in Early Cancer Diagnosis With Blood-Based Tests
A new white paper published by the USC Schaeffer Center focuses on multi-cancer, early detection, (MCED) blood-based tests as one solution to reduce disparities in late-stage cancer diagnosis among minority populations.
Posted in -
Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members
A new Schaeffer Center study comparing Medicare Part D prescription drug prices with those paid by Costco members finds that the federal government overpaid on roughly half of the most common generic medicines in 2018.
Posted in -
USC Research Shows Costco Beats Medicare in Generic Drug Savings Nearly 50% of the Time
Intermediaries negotiate good prices, but lack incentives to pass savings to beneficiaries and taxpayers.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Developing Effective Payment and Reimbursement Models
Targeted therapies can come with significant costs. But successful use of personalized medicine can also result in better healthcare outcomes and reduced long-term costs over time. Given this, how we pay for these therapies may require new approaches and models.
-
Leveraging Precision Medicine to Meet Patient Needs
Precision medicine promises to reduce adverse side effects and time-consuming trial and error processes, but many patients do not know what it is and providers struggle to leverage it effectively.
-
Cost- Effectiveness of Total State Coverage for Hepatitis C Medications
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years.
Categorized in -
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Categorized in -
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
Research from Schaeffer Center experts Darius Lakdawalla and Meng Li in JAMA Network Open finds U.S. insurers could use drug manufacturer rebates to lower retail pharmacy prices and reduce patient out-of-pocket burden by 38% on average, or 70% in the most competitive drug classes.
Categorized in -
Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer
A new Schaeffer Center study analyzes the link between targeted therapies and outcomes among Medicare patients newly diagnosed with breast cancer, finding targeted therapies used in advanced-stage cancers improved mortality, whereas patients with early-stage cancers had little improvement in mortality from targeted drugs.
Categorized in